A single study suggested CRABP2 to acts as a tumor inhibitor in esophageal carcinoma (Yang et al. 2016), while in breast cancer, CRABP2 can both suppress or promote tumor invasion depending on tumor type (Feng et al. 2019). This evidence concerns the gene CRABP2 and breast cancer.